MYRIAD GENETICS INC (MYGN)

Myriad Genetics is the United States’ largest provider of DNA testing for hereditary cancer risk and personalized medicine. Trading under the ticker MYGN and filing with the SEC under CIK 899923, Myriad operates in a sector that sits at the intersection of healthcare, consumer genetics, and information technology—interpreting the human genome to flag disease risk and guide clinical care.

How the Business Works

Myriad makes money by running genetic tests. A patient or their doctor orders one of Myriad’s assays—a structured lab procedure that sequences DNA and searches for mutations linked to disease. The company bills insurers, Medicare, and self-pay patients for these tests. The core offering is the BRACAnalysis test, which screens for mutations in BRCA1 and BRCA2 genes—inherited variants that sharply raise the risk of breast and ovarian cancer in women and prostate cancer in men. This test became famous after high-profile public figures disclosed positive results and chose preventive surgery.

Beyond BRCA, Myriad offers panels for hereditary colon cancer (Lynch syndrome), hereditary melanoma, hereditary heart disease, and psychiatric conditions like depression and anxiety. Each test follows the same pattern: a patient provides a saliva or blood sample, Myriad’s lab processes it, bioinformatics software flags relevant mutations, and a genetic counselor interprets the results for the ordering physician.

The revenue model is straightforward. Insurance companies pay per test. Myriad negotiates rates with major payers. For uninsured patients, Myriad often absorbs the cost or accepts reduced payment—a practice called “test at risk” that builds volume and loyalty. The economics are favorable once the infrastructure is in place: a test costs the company roughly $300 to $500 in lab labor and materials but can generate $2,000 to $4,000 in gross revenue, yielding margins that reward scale.

Position in Precision Medicine

Myriad holds a dominant market position in hereditary cancer testing in the United States. It was the first mover in commercial BRCA testing, launched its own branded test in the 1990s, and built clinical relationships that persist. This first-mover position was reinforced by regulatory gatekeeping: genetic testing labs must meet Clinical Laboratory Improvement Amendments (CLIA) standards, and Myriad’s long track record made it trusted by physicians and payers.

The competitive landscape has shifted. Other laboratories—Quest Diagnostics, LabCorp, Invitae (now owned by Labcorp)—now offer similar tests. But Myriad remains the incumbent with the broadest test menu and the deepest integration into oncology and cardiology practices. Myriad also owns RiskScore, a software platform that helps health systems manage genetic risk at the population level, creating stickiness beyond single tests.

Reimbursement Risk and Regulation

Myriad’s business depends on insurance reimbursement. If payers suddenly denied coverage or cut rates sharply, revenue would crater. This risk is real. In 2013, a Supreme Court decision ruled that naturally occurring DNA cannot be patented—a blow that invalidated some of Myriad’s claims around BRCA testing exclusivity, though it did not eliminate its market position.

Genetic testing itself is regulated by the FDA as a Laboratory Developed Test (LDT). The regulatory framework has been in flux, with the FDA gradually asserting more oversight. Myriad must maintain CLIA accreditation and show that its tests are accurate and clinically useful. The company invests heavily in validation studies and publishes research to buttress its claims about test utility.

Revenue Diversification

Myriad began as a cancer-testing company but has expanded into mental health (psychiatry panel) and cardiology (familial hypercholesterolemia, arrhythmia risk). This diversification spreads risk across conditions and patient populations. The mental health arm, in particular, taps a large addressable market—millions of patients with depression, anxiety, and bipolar disorder might benefit from pharmacogenomic insight into which medications are likely to work.

The company also acquired MyRisk, a risk-assessment technology that helps women understand their cumulative breast cancer risk beyond genetics, incorporating family history and other factors.

How to Research Myriad

Start with Myriad’s 10-K annual filing to the SEC. The “Business” section details the test menu and which conditions each targets. The “Risk Factors” section is candid about reimbursement pressure, competition, and regulatory uncertainty. Look for the proportion of revenue from BRCA versus other tests; over-reliance on BRCA would indicate business concentration.

The quarterly earnings calls, filed as 8-K transcripts, discuss payer negotiations and volume trends. If Myriad reports that a major insurer tightened coverage or cut payment rates, that signals headwind. Conversely, expansion into new indications and geographic markets suggests growth levers.

Genetic testing is a field in which the published medical literature matters. Peer-reviewed studies on the clinical utility of Myriad’s tests lend credibility. If Myriad’s own research shows positive outcomes, that supports its sales pitch to ordering physicians and health systems.